Amgen and Dompe Biotec to Combine Commercial Operations in Italy

Puntúa la noticia :

Nota de los usuarios: - (0votos)

Share

Tweet

elEconomista.es en Twitter

Follow @eleconomistaes

EcoTablet - ¡Gratis en App Store!

La plataforma más completa de información y servicios económicos para iPad.

• Suscribirse al boletín
• Imprimir
• Enviar
• Aumentar texto
• Reducir texto
• Haga doble click sobre una palabra para ver su signifcado
• Sudoku: Juega cada día a uno nuevo
• El tiempo: Consulta la previsión para tu ciudad

Single Company for Amgen Products in New Arrangement

Amgen, the world's largest biotechnology company and Dompe Biotec,
S.p.A., its co-marketing partner in Italy, announced today that they
have agreed to combine their current commercial operations with
respect to Amgen products under a single company to be called
Amgen-Dompe S.p.A.

Based in Milan, Amgen-Dompe will be organised as an Amgen
affiliate and comprise current Amgen and Dompe staff plus current
Amgen R&D staff in Italy.

The president of Amgen-Dompe will be Eugenio Aringhieri, who is
currently president and chief executive officer of Dompe Biotec, while
Marco Renoldi, currently managing director of Amgen Italy, will serve
as its managing director. The Board will be made up of four Amgen
members and three Dompe members.

"This new arrangement will make our operations in Italy stronger
and better organised to achieve sustained long-term growth and
continued commitment to excellence in service to patients," said Rolf
Hoffmann, senior vice president, Amgen International Commercial
Operations.

"With a legacy of 16 years of successful relations, we are
embarking on a new era that will combine both companies' knowledge and
expertise to underpin a firm business future for the benefit of our
customers and our patients," said Sergio Dompe, president of Dompe
Farmaceutici - Dompe Biotec Holding Company - who will have a seat on
the Board of Directors of Amgen International AG, a subsidiary of
Amgen International, Inc.

About Amgen

Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com

About Dompe Biotec

Dompe Biotec, a Dompe Group company, was established in 1988 and
specializes in the marketing of biotech drugs with a high therapeutic
profile in the oncological, haematological and nephrological areas.
These drugs have specialized uses and are mostly employed in
hospitals.

Dompe Biotec operates with the objective of making a contribution
to improving the quality of people's lives. It does so by providing
therapeutic health solutions for the health and wellbeing of mankind,
and it is a key partner for the scientific community.

Dompe Biotec's primary objective is to achieve an excellent
positioning in the therapeutical areas in which it operates, with
utmost focus on the identification of innovative products which will
make a major contribution to patient health.

PUBLICIDAD

- Recibe nuestros análisis Diarios sobre Divisas, Acciones y Opciones. ¡Apúntate ya! ¡Es GRATIS!

- Opere en más de 8.000 CFDs. Infórmese y obtenga su CFD Trading Guide

- Nuevos spreads en materias primas: Oro tan sólo 0,3 puntos, Plata 0,25, Petróleo 0,35

- Opera desde 2,95 € en tiempo real con Self Bank.